Your search for ‘Spruson & Ferguson’ returned 1,284 results

Australian owned golf company has gained a Sports Medicine Australia (SMA) recommendation for its golf buggy.

The Commissioner of Patents is able to extend the time within which to apply for a pharmaceutical patent term extension.

Life sciences patents must be drafted carefully to ensure that they meet the new US patentability threshold requirements.

The Registrar found that use of the Opposed Mark was unlikely to mislead or deceive, or amount to passing off.

IP Australia has updated its practice concerning letters of consent.

The ACIP have now released their Issues Paper and several areas have been highlighted for comment.

Trademark owners should also be vigilant in protecting and enforcing their trademark rights in a timely manner.

Some fees will be reduced or eliminated while other fees will increase, for Australian patents and patent applications.

In the recent decision of Chiropedic Bedding Pty Ltd v Radburg Pty Ltd [2009] FCA 1163, in which a design for a bedding ensemble comprising a mattress and base was found to be valid and infringed, the Federal Court of Australia considered some key issues relating to the assessment of validity and infringement of registered designs. More particularly, it focused on the effect of identifying novel features in the design application.

Discusses the new R&D Tax Credit incentive being introduced by the Federal Government.

On 12 May, 2017 the CFDA published its intention to work on a new patent linkage and data protection system for China as part of a reform of its regulatory approval processes (2017 Policy Notice No. 55).

Rectification notice mandates applicants provide preliminary evidence.

The accurate translation of patent documents is crucial to circumvent potential invalidation or infringement disputes in China.

The Indonesian Patent Office recently issued new patent examination guidelines to clarify medical use claims.

This article reports continuing progress toward New Zealand’s new Patents Act 2006.

Recent IPONZ decision has highlighted one of the difficulties relating to formulating and construing Swiss-style claims.

On 2 September 2004, Singapore parliament passed new legislation which regulates human cloning and other related activities. The Human Cloning and Other Prohibited Practices Act (hereinafter referred to as "The Act") came into force on 1 October 2004. The Act is adapted from various provisions in the Australian Prohibition of Human Cloning Act 2002.